Roivant Sciences Ltd (ROIV) Stock Price, Quote & News

Company Profile

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythemat...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7400 3347

Website: roivant.com

Address:

50 Broadway, 7th Floor, London, United Kingdom

WAJeff Jan. 14 at 7:51 PM

$ROIV $23.76 52 week high

0 · Reply

DocPharm Jan. 13 at 4:55 PM

$ROIV the gem that keeps getting shinier ;)

0 · Reply

DocPharm Jan. 13 at 4:55 PM

$ABUS food for thought - Zero ABUS presentations to shareholders since the quiet period announcement Only presentation has been regarding Genevant at $ROIV R&D day Very little communication to SH since - Only those required by law Reminder $ROIV overhauled the Exec team and BoD last year

1 · Reply

J_Wayne Jan. 13 at 4:43 PM

$ROIV interesting

1 · Reply

ccdemuth Jan. 12 at 7:57 PM

$WLFC $CFNB $GDEN $LQDA $ROIV https://seekingalpha.com/article/4858893-chris-demuth-jr-shares-some-stock-picks

0 · Reply

Shortsales Jan. 6 at 10:25 PM

$ABUS $ROIV $MRNA 🏁

1 · Reply

MWM Dec. 31 at 7:43 PM

Calls on $ABUS and $ROIV and puts on $MRNA???

0 · Reply

OfficialStocktwitsUser Dec. 29 at 7:09 PM

$ROIV RSI: 55.57, MACD: 0.5996 Vol: 0.93, MA20: 21.58, MA50: 20.48 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

solidflo Dec. 29 at 2:52 PM

$ABUS how much will we see if favorable judgement. Or does it majority go to $ROIV? Why is $ABUS so stale and why is $ROIV 10x when bought abus?

3 · Reply

GoingPrivateG Dec. 25 at 7:40 AM

$ROIV The valuation debate now centers on reliability of delivery, where each milestone now functions as a credibility checkpoint. Any drift in timelines risks renewed volatility.

0 · Reply

Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P.

Jan 8, 2026, 10:42 AM EST - 6 days ago

Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript

Dec 22, 2025, 11:25 PM EST - 22 days ago

Goldman Sachs Mid Cap Growth Fund Q3 2025 Investment Update

ALAB RDDT URI

Dec 12, 2025, 6:12 PM EST - 4 weeks ago

Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript

Dec 11, 2025, 7:30 AM EST - 4 weeks ago

Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day

Nov 18, 2025, 2:28 PM EST - 2 months ago

Roivant Sciences Ltd. (ROIV) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 13, 2025, 7:28 AM EST - 2 months ago

Roivant Sciences: Brepocitinib And Roadmap Still Underpriced

Nov 11, 2025, 10:31 AM EST - 2 months ago

Roivant Sciences Ltd. (ROIV) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 10, 2025, 12:31 PM EST - 2 months ago

Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript

Nov 10, 2025, 7:00 AM EST - 2 months ago

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

Oct 27, 2025, 4:10 PM EDT - 2 months ago

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

IMVT

Oct 27, 2025, 4:10 PM EDT - 2 months ago

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Sep 25, 2025, 2:47 AM EDT - 3 months ago

Roivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 24, 2025, 10:57 PM EDT - 3 months ago

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 23, 2025, 5:45 AM EDT - 4 months ago

Roivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call Transcript

Sep 17, 2025, 3:43 PM EDT - 4 months ago

Roivant Sciences Ltd. - Special Call

Sep 17, 2025, 12:13 PM EDT - 4 months ago

Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial

Sep 17, 2025, 8:21 AM EDT - 4 months ago

Roivant, Priovant Therapeutics' rare skin and muscle disease drug shows promise in trial

Sep 17, 2025, 7:00 AM EDT - 4 months ago

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

Sep 11, 2025, 4:30 PM EDT - 4 months ago

Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List

Sep 8, 2025, 8:25 PM EDT - 4 months ago

Roivant Sciences Ltd. (ROIV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 7:00 AM EDT - 4 months ago

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Sep 3, 2025, 11:07 PM EDT - 4 months ago

Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-Of-Concept Study Remission Data Transcript

Sep 3, 2025, 1:01 PM EDT - 4 months ago

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Aug 15, 2025, 9:30 AM EDT - 5 months ago

Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack

Aug 11, 2025, 12:28 PM EDT - 5 months ago

Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript

Aug 11, 2025, 7:00 AM EDT - 5 months ago

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

Jul 28, 2025, 4:05 PM EDT - 6 months ago

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

Jun 16, 2025, 7:00 AM EDT - 7 months ago

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

Jun 9, 2025, 4:05 PM EDT - 7 months ago

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

May 29, 2025, 2:17 PM EDT - 8 months ago

Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript

May 29, 2025, 7:00 AM EDT - 8 months ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

May 15, 2025, 4:10 PM EDT - 8 months ago

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

Apr 23, 2025, 12:13 PM EDT - 9 months ago

Roivant Sciences: Primed For Growth With A De-Risked Pipeline

Apr 21, 2025, 7:00 AM EDT - 9 months ago

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

Mar 19, 2025, 7:45 AM EDT - 10 months ago

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Mar 18, 2025, 4:32 PM EDT - 10 months ago

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Mar 3, 2025, 9:15 AM EST - 11 months ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ABUS

Feb 10, 2025, 12:32 PM EST - 1 year ago

Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript

Feb 10, 2025, 7:00 AM EST - 1 year ago

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

Feb 5, 2025, 12:12 PM EST - 1 year ago

Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)

Feb 3, 2025, 7:00 AM EST - 1 year ago

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

Jan 29, 2025, 4:05 PM EST - 1 year ago

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development

Dec 4, 2024, 8:30 AM EST - 1 year ago

Roivant Sciences: A Biotech Growth Play With Major Ambitions

Dec 3, 2024, 7:19 AM EST - 1 year ago

Roivant's lung disease drug fails mid-stage trial

Nov 12, 2024, 2:41 PM EST - 1 year ago

Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript

Oct 29, 2024, 4:35 PM EDT - 1 year ago

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

Oct 22, 2024, 12:31 PM EDT - 1 year ago

Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility

Sep 18, 2024, 3:20 PM EDT - 1 year ago

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

OGN

WAJeff Jan. 14 at 7:51 PM

$ROIV $23.76 52 week high

0 · Reply

DocPharm Jan. 13 at 4:55 PM

$ROIV the gem that keeps getting shinier ;)

0 · Reply

DocPharm Jan. 13 at 4:55 PM

1 · Reply

J_Wayne Jan. 13 at 4:43 PM

$ROIV interesting

1 · Reply

ccdemuth Jan. 12 at 7:57 PM

$WLFC $CFNB $GDEN $LQDA $ROIV https://seekingalpha.com/article/4858893-chris-demuth-jr-shares-some-stock-picks

0 · Reply

Shortsales Jan. 6 at 10:25 PM

$ABUS $ROIV $MRNA 🏁

1 · Reply

MWM Dec. 31 at 7:43 PM

Calls on $ABUS and $ROIV and puts on $MRNA???

0 · Reply

OfficialStocktwitsUser Dec. 29 at 7:09 PM

0 · Reply

solidflo Dec. 29 at 2:52 PM

$ABUS how much will we see if favorable judgement. Or does it majority go to $ROIV? Why is $ABUS so stale and why is $ROIV 10x when bought abus?

3 · Reply

GoingPrivateG Dec. 25 at 7:40 AM

$ROIV The valuation debate now centers on reliability of delivery, where each milestone now functions as a credibility checkpoint. Any drift in timelines risks renewed volatility.

0 · Reply

WAJeff Dec. 24 at 4:35 PM

Added $ROIV 22.60. Big miss not being in this, considering I was actively trading it in the $11-12 range from Dec 2023 to March 2024. Sucks for Vivek that he sold shares to pay for his stupid presidential campaign. January 2024 was the exact wrong time to be selling this.

0 · Reply

NakdEnergy Dec. 24 at 2:57 PM

$ABUS how much of $ROIV’s 190% launch is on our back?

1 · Reply

NakdEnergy Dec. 24 at 1:02 PM

$ABUS $ROIV up 90+ % in 1 year? Must have something to do with them basically owning/running $ABUS….

1 · Reply

OfficialStocktwitsUser Dec. 24 at 12:54 PM

$ROIV RSI: 62.81, MACD: 0.7224 Vol: 0.91, MA20: 21.38, MA50: 20.16 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

DocPharm Dec. 23 at 4:30 PM

$ROIV don’t listen to paid bashers Diff handles have been saying the same stuff since sub $7

0 · Reply

TechWillCrash Dec. 23 at 11:16 AM

$ROIV What fraud does the dirty little indian from Ohio have planned now?

0 · Reply

NoBSPls Dec. 19 at 7:39 PM

$ROIV Somebody...anybody?? Any news/rumors?

0 · Reply

DocPharm Dec. 18 at 4:38 PM

$ROIV bearish divergence on the 3 month, daily chart However, still looks like indecision Will they give us a nice Hannukah & Christmas gift of a sub $20 add 🌲🎁

1 · Reply

5htc2 Dec. 18 at 3:46 PM

$ROIV well deserved stock options acquired and then sold by Matt (were set to expire in 2026) fwiw he owns 17.5M shares.

0 · Reply

Alfalcon Dec. 18 at 12:13 AM

$ROIV

0 · Reply

Market Cap	15.41B
Revenue (ttm)	29.05M
Net Income (ttm)	-171.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-592.01%
Debt to Equity Ratio	0.00

Volume	5,806,100
Avg Vol	7,811,852
Day's Range	N/A - N/A
Shares Out	695.49M
Stochastic %K	95%
Beta	1.22
Analysts	Strong Sell
Price Target	$27.00